Get started
Author

Trevor Beattie

Observed names: Beattie T, Beattie, Trevor, T Beattie, T. Beattie
OpenAlex ID: A5017748824
Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial
2021 · Robert S Wallis, Sibuse Ginindza, et al. · The Lancet Respiratory Medicine · 144
PDF
Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial
2020 · Kelly E Dooley, Radojkam Savic, et al. · The Lancet HIV · 65
Safety and Immunogenicity of H1/IC31®, an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial
2014 · Klaus Reither, Lynn Katsoulis, et al. · PLoS ONE · 62
PDF
Safety, bactericidal activity, and pharmacokinetics of the antituberculosis drug candidate BTZ-043 in South Africa (PanACEA-BTZ-043–02): an open-label, dose-expansion, randomised, controlled, phase 1b/2a trial
2025 · Norbert Heinrich, Veronique de Jager, et al. · The Lancet Microbe · 30
PDF
Sutezolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-SUDOCU-01): a prospective, open-label, randomised, phase 2b dose-finding trial
2025 · Norbert Heinrich, Norbert Heinrich, et al. · The Lancet Infectious Diseases · 20
PDF
Lung and blood early biomarkers for host-directed tuberculosis therapies: Secondary outcome measures from a randomized controlled trial
2022 · Robert S. Wallis, Sibuse Ginindza, et al. · PLoS ONE · 20
PDF
Delpazolid in combination with bedaquiline, delamanid, and moxifloxacin for pulmonary tuberculosis (PanACEA-DECODE-01): a prospective, randomised, open-label, phase 2b, dose-finding trial
2025 · Lilian Tina Minja, Isabella van der Feltz, et al. · The Lancet Infectious Diseases · 18
PDF
Sequencing Mycobacteria and Algorithm-determined Resistant Tuberculosis Treatment (SMARTT): a study protocol for a phase IV pragmatic randomized controlled patient management strategy trial
2022 · Annelies Van Rie, Elise De Vos, et al. · Trials · 16
PDF
Simultaneous initiation of dolutegravir-based antiretroviral therapy and once-weekly rifapentine and isoniazid for tuberculosis prevention in antiretroviral-naive people with HIV: an open-label, non-randomised, phase 1/2 trial
2025 · Ethel D Weld, Trevor Beattie, et al. · The Lancet HIV · 9
Cardiac safety of bedaquiline, delamanid and moxifloxacin co-administered with or without varying doses of sutezolid or delpazolid for the treatment of drug-susceptible TB
2025 · Simon E Koele, Krista Stoycheva, et al. · Journal of Antimicrobial Chemotherapy · 5
PDF
Preliminary Results of an Experimental Medicine Trial of Adjunctive Host-Directed Therapy in Adults with Moderately or Far-Advanced Rifampin-Susceptible Pulmonary Tuberculosis
2019 · R.S. Wallis, S. Ginindza, et al. · 5
panTB-HM: a multi-arm clinical trial of a pan-TB regimen targeting both host and microbe
2026 · D. Mudzengi, S. Mashatole, et al. · Trials · 2
Safety and immunogenicity of a single dose of Ad26.COV2.S, BNT162b2, or SARS-CoV-2-rS-protein-nanoparticle in previously vaccinated and unvaccinated adults living with and without HIV in South Africa: a phase 2a randomised, observer-blind trial
2026 · Vaneshree Govender, Tarylee Reddy, et al. · The Lancet HIV · 1
A71-06 Safety and Treatment Completion of 1 Versus 3 Months of Isoniazid and Rifapentine (HP) in Household Contacts of People With Tuberculosis: The One-to-Three Trial
2026 · R E Chaisson, J Moodley, et al. · American Journal of Respiratory and Critical Care Medicine
A71-04 Novel 4-month Pan-TB Regimens Promoting Recovery of Lung Function: Preliminary Findings of the PanTB-HM Phase 2c Trial
2026 · R S Wallis, D Mudzengi, et al. · American Journal of Respiratory and Critical Care Medicine
One Month Daily or Three Months Weekly Isoniazid-Rifapentine for Tuberculosis Prevention in Pregnant Women With HIV Receiving Dolutegravir-Based Antiretroviral Therapy (DOLPHIN Moms): A Randomized Trial
2026 · Sylvia M. LaCourse, Vaneshree Govender, et al. · SSRN Electronic Journal
PDF
Randomised Trial of a Single Dose of Ad26.COV2.S, BNT162b2 or SARS-CoV-2-rS-PN in Previously Vaccinated and Unvaccinated Adults Living with and without HIV in South Africa: Safety and Immunogenicity
2025 · Vaneshree Govender, Tarylee Reddy, et al. · SSRN Electronic Journal
Simultaneous Initiation of Dolutegravir-Based Antiretroviral Treatment and Once-Weekly Rifapentine and Isoniazid (3HP) for Tuberculosis Prevention in Antiretroviral-Naïve People with HIV: A Phase 1/2 Trial
2024 · Ethel Derby Weld, Trevor Beattie, et al. · SSRN Electronic Journal
Oc 8711 Early Biomarkers of Lung Inflammation and Function in Trials of Host-directed Tuberculosis Therapies (tb-hdt)
2019 · Robert Wallis, Trevor Beattie, et al. · BMJ Global Health
PDF
Works count: 23
Citation count: 402
H-index: 9
I10-index: 8
Year
Topic
Type